RE:PMN Announces Strategic Priorities for 2021 How much longer for a Phase 1 clinical trial. Well we seem to be tied at the hip with aducanumab.
"The positive FDA Medical Review relating to Biogen’s regulatory submission of aducanumab for Alzheimer’s disease (AD) was followed by a negative Advisory Committee recommendation on November 6, 2020. Discussions with institutional investors and bankers prior to the Advisory Committee vote suggested that a positive vote would have facilitated capital availability for the costly IND enabling work on PMN310, a prospect now delayed by the negative vote. "
"We remain committed to moving PMN310 forward as soon as the funding window re-opens. "
G1945V